, Volume 235, Issue 11, pp 3083–3091 | Cite as

The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug

  • Baland JalalEmail author
Open Access
Theoretical and Methodological Perspective


Sleep paralysis is a state of involuntary immobility occurring at sleep onset or offset, often accompanied by uncanny “ghost-like” hallucinations and extreme fear reactions. I provide here a neuropharmacological account for these hallucinatory experiences by evoking the role of the serotonin 2A receptor (5-HT2AR). Research has shown that 5-HT2AR activation can induce visual hallucinations, “mystical” subjective states, and out-of-body experiences (OBEs), and modulate fear circuits. Hallucinatory experiences triggered by serotonin—serotonergic (“pseudo”) hallucinations, induced by hallucinogenic drugs—tend to be “dream-like” with the experiencer having insight (“meta-awareness”) that he is hallucinating, unlike dopaminergic (“psychotic” and “life-like”) hallucinations where such insight is lost. Indeed, hallucinatory experiences during sleep paralysis have the classic features of serotonergic hallucinations, and are strikingly similar to perceptual and subjective states induced by hallucinogenic drugs (e.g., lysergic acid diethylamide [LSD] and psilocybin), i.e., they entail visual hallucinations, mystical experiences, OBEs, and extreme fear reactions. I propose a possible mechanism whereby serotonin could be functionally implicated in generating sleep paralysis hallucinations and fear reactions through 5-HT2AR activity. Moreover, I speculate on the role of 5-HT2C receptors vis-à-vis anxiety and panic during sleep paralysis, and the orbitofrontal cortex—rich with 5-HT2A receptors—in influencing visual pathways during sleep paralysis, and, in effect, hallucinations. Finally, I propose, for the first time, a drug to target sleep paralysis hallucinations and fear reactions, namely the selective 5-HT2AR inverse agonist, pimavanserin. This account implicates gene HTR2A on chromosome 13q as the underlying cause of sleep paralysis hallucinations and could be explored using positron emission tomography.


Sleep paralysis Hypnogogic Hypnopompic Hallucinations Serotonin 2A Hallucinogenic drugs Mystical experiences Ketanserin Treatment 

I have heard (but not believed), the spirits of the dead

May walk again. If such thing be, thy mother

Appeared to me last night; for ne’er was dream

So like a waking.



During rapid eye movement (REM) sleep, we experience vivid dreams. If we were to act out these dreams, we would risk hurting ourselves. So the brain has an ingenious solution: it leaves our body temporarily paralyzed. This paralysis is triggered by the pons (the pontine reticular formation) and ventromedial medulla that suppress skeletal muscle tone via interneurons of the spinal cord, through the inhibitory neurotransmitters GABA and glycine (Brooks and Peever 2012; Jalal and Hinton 2013; Kandel et al. 2000). However, the perceptual and motor aspects of REM sleep can occasionally decouple such that the sleeper begins to awaken before muscle paralysis has waned. The result is a curious condition called sleep paralysis, where the person is temporarily paralyzed (from REM postural atonia)—yet perceptually alert (or semi-alert) (Hobson 1995). Sleep paralysis victims often complain of hypnogogic and hypnopompic hallucinations, such as seeing space aliens and shadow-people in their bedroom (Cheyne et al. 1999a, b; Jalal et al. 2014b, 2015a, 2017, in press[a]; Jalal and Ramachandran 2014, 2017; McNally and Clancy 2005).

While the mechanism underlying sleep paralysis atonia is established (Brooks and Peever 2012), in comparison, relatively little is known about the pathophysiology of the uncanny hallucinations that can accompany these episodes. During sleep paralysis, for instance, there is a desynchrony between motor-execution (efference) and sensory input from the body (afference), resulting in massive deafferentation. This neural deafferentation may lead to “body image” distortions, entailing a functional disturbance of the multisensory processing of body and self at the temporoparietal junction (TPJ) and the right superior parietal lobule (SPL)—structures crucial for the construction of a neural representation of the body (Jalal and Ramachandran 2014). This account is broadly consistent with the finding that disrupting the TPJ using focal electrical stimulation can induce the feeling of an illusory “other” shadow-like person mimicking one’s body postures (Arzy et al. 2006), and that hyperactivity in the temporoparietal cortex of patients with schizophrenia can lead them to misattribute their own actions to others (Farrer et al. 2004). One hypothesis has also implicated the mirror neuron system, and the interaction between several brain regions, including the prefrontal cortex and sensory feedback, as contributing factors in triggering these hallucinations (Jalal and Ramachandran 2017). (On the mirror neuron system see also, Ramachandran 2012; Rizzolatti et al. 1996, 2001). It is indeed plausible that sleep paralysis hallucinations (“ghosts” and out-of-body experiences [OBEs]) arise from the interaction of multiple brain systems and the synergistic influence of several mechanisms.

To date, no account has been provided for the possible neuropharmacological basis of these “ghostly” hallucinations during sleep paralysis. As we shall see, serotonin 2A receptor (5-HT2AR) activation may play a crucial role in inducing these hallucinations.

The role of orexin-hypocretin in promoting wakefulness

The neuropeptide orexin (orx-a/hcrt1 and orx-b/hcrt2)—originating in the hypothalamus—is central for keeping us awake. Orexin neurons turn on when we are awake and switch off when we sleep. A neurodegenerative loss of these “wakefulness neurons” results in the debilitating sleep disorder, narcolepsy (Bayer et al. 2004). It is hardly surprising that narcoleptic patients have difficulties staying awake. Orexin neurons in the hypothalamus project to various brain regions, including somatosensory, visual, motor, and cingulate cortices, where their excitatory effects promote wakefulness. They stimulate noradrenaline neurons in the locus coeruleus, histamine neurons, and cholinergic basal forebrain neurons (Brown et al. 2002; Eggermann et al. 2001; Eriksson et al. 2001; Hagan et al. 1999; Horvath et al. 1999; Huang et al. 2001; Ivanov and Aston-Jones 2000; see also Bayer et al. 2004; for a review, see Sakurai 2007). Orexin neurons also project to the dorsal raphé nucleus (DRN) to excite serotonin (5-HT) neurons (Aghajanian and Marek 1999). The DRN is virtually a “hub” for serotonin neurons (Liu et al. 2002). One feature of serotonin neurons in the DRN is that they stop firing during REM sleep, suggesting that the DRN functions as the REM sleep inhibitory area (Ursin 2002). In fact, the primary role of serotonin is to promote wakefulness and inhibit REM sleep.

Serotonin 2A receptor activation: hallucinations, mystical experiences, OBEs, personal meaning, and paranoia

The serotonin receptors activated by serotonin—mediating both excitatory and inhibitory neurotransmission—include seven major subtypes, namely 5-HT1–7. Moreover, 5-HT1 receptors include 5-HT1A, 5-HT1B, and 5-HT1D; also, 5-HT2 receptors include 5-HT2A, 5-HT2B, and 5-HT2C subtypes (e.g., Riva 2016; for a review, see Saulin et al. 2012).

Serotonin 2A (5-HT2A) receptors are of special interest. Molecular, pharmacological, and neuroimaging research demonstrate the central role of 5-HT2A receptors in mediating visual processing and visual hallucinations. Indeed, there are a high number of 5-HT2A receptors in the visual cortex (Gerstl et al. 2008; Moreau et al. 2010). Alterations of the density of 5-HT2A receptors in the visual cortex of patients with schizophrenia and Parkinson’s disease are associated with experiencing visual hallucinations (González-Maeso et al. 2008; Huot et al. 2010). Pimavanserin, the 5-HT2A receptor inverse agonist, is used to treat visual hallucinations in Parkinson’s disease (Meltzer et al. 2010). Interestingly, 5-HT2A receptors mainly mediate the visual hallucinations—and indeed uncanny mystical experiences and altered states of consciousness—that are induced by hallucinogenic drugs like lysergic acid diethylamide (LSD), mescaline, and psilocybin (e.g., Griffiths et al. 2008; Vollenweider and Kometer 2010; on hallucinogens vis-à-vis 5-HT2AR, see also Nichols 2004). Research has shown that 5-HT2A receptor activation induces visual hallucinations by increasing cortical excitability and altering visual-evoked cortical responses and that these effects of psilocybin on the visual system are blocked with the 5-HT2A receptor antagonist ketanserin (Kometer et al. 2013).

5-HT2AR activation also selectively affects self-representation in fronto-parietal cortical regions, including the default mode network (DMN; Raichle et al. 2001) (e.g., Tagliazucchi et al. 2016; Carhart-Harris et al. 2012). The DMN is known to mediate processing of self-related information and neural self-constructs (Buckner et al. 2008). For instance, as noted above, the TPJ (a region of the DMN) is directly implicated in OBEs and hallucinating human-like figures (Arzy et al. 2006). The fact that 5-HT2A receptors are distributed in higher-level cortical networks such as the DMN including the TPJ is consistent with findings that hallucinogenic drugs like psilocybin and LSD (5-HT2AR agonists) can induce OBE-type events, e.g., feelings of derealization and “ego dissolution” (e.g., Lebedev et al. 2015; Tagliazucchi et al. 2016). Also, one study in patients with depersonalization disorder found that short-term hallucinogen use could induce chronic symptoms of depersonalization (i.e., having a “fragmented sense of self”) (Simeon et al. 2003).

Moreover, research suggests that 5-HT2A receptor activation underlies the propensity to ascribe meaning to “meaningless” stimuli. A recent study (Preller et al. 2017) found that activation of 5-HT2A receptors, when induced by LSD—aside from generating hallucinations and feelings of “separateness from the self” (i.e., OBE-type states), leads to greater attribution of personal relevance to otherwise meaningless cues. This indicates that the 5-HT2A receptor might play a role in the dysfunctional “personal relevance attribution” seen in psychiatric disorders such as schizophrenia; that is, all too often, patients with schizophrenia and related psychotic disorders find personal meaning in situations or places most healthy people interpret as meaningless (Preller et al. 2017). In fact, this may explain why the 5-HT2A receptor is upregulated in untreated patients with schizophrenia (González-Maeso and Sealfon 2009), and indeed, many second-generation antipsychotic drugs precisely have an antagonistic effect on 5HT2A receptors, stressing the possible role of 5HT2A receptor activation in schizophrenia (Meltzer and Massey 2011; Rolland et al. 2014). Consistent with previous research, the aforementioned study found that the 5HT2AR antagonist ketanserin was able to block these effects of 5-HT2A receptors (Preller et al. 2017).

Serotonin 2A receptors are also densely concentrated in the limbic system and are important for mediating the emotion of fear. There is evidence showing that the processing of emotionally salient information is modulated by the 5HT2A receptor and that the expression of these receptors constitutes a trait related to anxiety (Frokjaer et al. 2008). Individuals with higher serotonin activity tend to have more fearful personalities, and interestingly, animals with a deficiency of 5-HT2A receptors lack normal fear reactions (Nelson 2010). One study found that the 5-HT2A receptor exerts influence on medial prefrontal regions which regulate the amygdala during fight-or-flight reactions (Fisher et al. 2009). Unsurprisingly, individuals under the influence of psilocybin may occasionally have extreme fear reactions and experience paranoia (Griffiths et al. 2006). The fear experienced when under the influence of hallucinogenic drugs manifests as hallucinations, paranoid delusions, and panic-like attacks. Taken together, the 5-HT2A receptor appears to drive both visual hallucinations and the propensity to ascribe meaning to “meaningless” cues, and likewise profoundly modulates circuits intertwining fear and mystical experiences.

Sleep paralysis hallucinations and serotonin 2A receptor activation

Ordinarily when waking from sleep, “arousal systems” become activated: orexin-producing neurons project both directly to cortical sites and critically the DRN (the so-called REM sleep inhibitory area) (Aghajanian and Marek 1999); in the DRN, these orexin neurons excite serotonin-producing neurons that in turn promote cortical arousal (Bayer et al. 2004; on serotonergic effects on REM sleep, see Pace-Schott 2008). By comparison, during sleep paralysis, there is likewise a transition from sleep (i.e., REM) to wakefulness, which involves activation of the same neural circuitry (i.e., wake-promoting neurons), but unlike normal wakefulness, the sleeper remains temporarily paralyzed (due to ongoing postural atonia), in spite of such activation of cortical and behavioral arousal mechanisms (i.e., wakefulness). That is, polysomnogram (PSG) recordings show that sleep paralysis is characterized by the curious persistence of REM atonia (indexed by a tonic electromyogram [EMG]) into wakefulness (i.e., shown by abundant bursts of “waking” alpha electroencephalogram [EEG] patterns) (Takeuchi et al. 1992). In other words, sleep paralysis is a unique dissociated state with simultaneous elements of both REM and wakefulness (different from other sleep states)—i.e., with the sleeper being “immobilized” yet perceptually awake (or “semi-awake”). It is plausible that during sleep paralysis, the activation of the serotonergic arousal system (i.e., phasic elevation of serotonin [i.e., via REM off cells]) to trigger perceptual wakefulness causes serotonin over-activity in the brain of the paralyzed sleeper. Serotonin could thus possibly be functionally implicated in generating sleep paralysis hallucinations through 5-HT2A receptor activity. Over-activation of 5-HT2A receptors during this peculiar “REM sleep-wake” state may in turn lead to massive increase in cortical excitability (e.g., in the visual cortex), elevated glutamate release in the neocortex affecting fronto-stratial glutamatergic pathways (including via medial prefrontal regions with high density of 5-HT2A receptors, e.g., in layer V pyramidal cells; see Aghajanian and Marek 1999), and enhanced amygdala activation. (Research specifically suggests that 5-HT2AR activation may enhance glutamate release (i.e., unto layer V pyramidal neurons) via presynaptic activity as opposed to a postsynaptic mechanism [Aghajanian and Marek 1999; for related work, see Marek and Aghajanian 1998a, b].) Indeed, while serotonin as an endogenous neurotransmitter is not regarded as hallucinogenic per se, metabolites of serotonin have a high affinity for 5-HT2A receptors and can trigger hallucinations in humans (Schmid and Bohn 2010). If this hypothesis is correct, and 5-HT2AR activation is functionally implicated in sleep paralysis hallucinations through the mechanism described here (or via a different mechanism), one should clearly see comparable neuropharmacological effects on the brain—and in turn subjective states of consciousness—both during sleep paralysis and when under the influence of hallucinogenic drugs. Below examples are provided of the similarities between subjective and perceptual states reported during sleep paralysis and those induced by drugs (5-HT2A receptor agonists) such as LSD and psilocybin.

Serotonergic hallucinations and sleep paralysis perceptual states

Serotonergic hallucinations (e.g., induced with psychedelic drugs) are sometimes referred to as “pseudo-hallucinations” or nonpsychotic hallucinations, and tend to be “dream-like” in nature. The experiencer can have perfect insight (“meta-awareness”) into the fact that these hallucinations are not real (Studerus et al. 2011; van der Zwaard and Polak 2001). On the contrary, hallucinations induced predominantly by D2Rs activation (“dopaminergic hallucinations”) are experienced as more “life-like” and crisp—as indistinguishable from real life—and with the person having lost complete insight into the fact that the hallucinations are not real. Dopaminergic hallucinations are also known as “psychotic hallucinations” and commonly seen in schizophrenia (Gaebel and Zielasek 2009). It is worth adding here that hallucinations induced via distinct pathways, that is, either 5-HT2A, D2Rs, or primarily NMDA blockage (“glutaminergic hallucinations”), can have partial overlapping neurobiological mechanisms. As noted, the 5-HT2A receptor may enhance glutamate release in prefrontal regions and LSD has been found to stimulate dopamine receptors, indicating the possible involvement of dopamine systems in LSD-induced hallucinations (Aghajanian and Marek 1999; Creese et al. 1975; see also, Vollenweider et al. 1998). But as described, the distinction in tonality between serotonergic “pseudo-hallucinations” and dopaminergic “psychotic hallucinations” is nonetheless phenomenologically robust (e.g., Aghajanian and Marek 1999; see also Rolland et al. 2014).

Hallucinatory experiences during sleep paralysis have the classic features of serotonergic hallucinations (“pseudo-hallucinations”) and are similar to those induced by hallucinogenic drugs. For example, sleep paralysis hallucinations tend to be “dream-like”—to the extent that the event itself sometimes is interpreted as a dream, especially so in cultures where there is no explanation or socio-cognitive framework for the experience (Fukuda et al. 2000). Moreover, during sleep paralysis, the sufferer can have ample awareness that he is in fact hallucinating (although this is not always the case) (i.e., “I know I am merely hallucinating this ‘ghost’ in front of me but it still feels real”) (e.g., Jalal et al. 2014b). Moreover, like hallucinogenic drugs, sleep paralysis is commonly associated with experiencing hallucinations that are “mystical” and “otherworldly” in nature. As noted, they often include seeing and sensing malevolent supernatural beings and having altered states of consciousness. Such OBEs can entail feelings of “dissociation” and “separation” from the “self” (e.g., autoscopy, derealization, and depersonalization states) (e.g., Cheyne and Girard 2009; Jalal and Ramachandran 2017). Like hallucinations produced by LSD for instance, hallucinatory experiences during sleep paralysis can include sensory distortions and the perception of colors and surfaces moving (e.g., Jalal et al. 2015a).

Sleep paralyzes hallucinations and “personal relevance attribution”

As described elsewhere (e.g., Jalal 2016), during sleep paralysis, the person may experience a series of co-occurring symptoms such as chest pressure and pain, difficulty breathing, spasms in limbs, and seeing a human-like shadowy figure. This shadowy figure is somewhat analogous to a Rorschach inkblot in that it is ambiguous per se. But during sleep paralysis, it is possible that 5-HT2A receptor activation could lead to the attribution of greater personal meaning to such endogenously generated cues (e.g., human-like shapes) and symptoms, for instance, drawing from autobiographical memories. This might be similar to the dysfunctional “personal relevance attribution” seen in psychotic disorders. In effect, these multisensory cues (visual, tactile, kinetic, etc.) are more likely to be interpreted in a personalized way and incorporated into an elaborate narrative, say, as a bedroom intruder (e.g., “Freddy Krueger”) approaching the helpless sleeper, pressing on his chest, and holding down his arms and legs, while attempting to rape or strangle him to death. Like experimentally induced multisensory experiences and illusions, for instance the rubber hand illusion (RHI), the Bayesian logic of all perceptual systems may play a role here (Botvinick and Cohen 1998; Jalal et al. 2015b), by allowing for top-down influence; the brain regards it as highly improbable that these somatic sensations and visual cues co-occur by random chance, and therefore builds a personally salient and meaningful narrative to account for them. Interestingly, given the link between serotonin and schizophrenia (González-Maeso and Sealfon 2009; Meltzer and Massey 2011; Rolland et al. 2014), multisensory illusions like the RHI are amplified in psychotic patients such as schizophrenics (Thakkar et al. 2011).

Sleep paralyses: paranoia and panic-like fear reactions

As commonly seen with hallucinogenic drugs, sleep paralysis almost always produces an overwhelming sense of fear, and like LSD and psilocybin, manifesting as terrifying hallucinations, paranoid delusions, and panic-like reactions (Cheyne and Pennycook 2013; Jalal et al. in press[b]; Jalal and Hinton 2013; Solomonova et al. 2008). Indeed, the experiencing of fear during sleep paralysis is one of its key features—reported in both the presence and absence of hallucinations (e.g., Jalal and Hinton 2013). There is no evidence to suggest that extreme fear reactions during sleep paralysis diminish after multiple episodes or having prior knowledge about the neurological roots of the experience—sleep paralysis on its own appears to activate amygdaloid fear circuitry at a core level. As such, the fear is not merely a result of realizing that one is paralyzed, catastrophic cognitions about the event (e.g., “I am dying”), and unpleasant somatic symptoms or hallucinations, although these almost certainly contribute to the underlying fear and can create a positive feedback loop (see “panic-hallucination” model; Jalal 2016, 2017).

The elevated fear levels seen during sleep paralysis are consistent with the well-established link between 5-HT2A receptor activation and fear reactions as described above (e.g., Fisher et al. 2009; Nelson 2010). It might explain why sleep paralysis almost always is reported as being terrifying worldwide, and rarely as a neutral or benign experience. Whether one experiences (serotonin-induced) fear and paranoia when taking hallucinogenic drugs depends on one’s environment and emotional state at the time of drug administration (Katz et al. 1968). These factors may play a role during sleep paralysis as well. But as sleep paralysis includes inherently unpleasant features (paralysis, chest pain, and difficulty breathing, potentially leading to activation of “threat hypervigilance systems” due to feelings of helplessness, etc. (Cheyne 2001; Jalal 2016), fear might be the most likely outcome. If one’s culture attributes sleep paralysis to pernicious supernatural forces (e.g., a “demonic attack”), such underlying fear could be enhanced due to further amygdaloid serotonin release. That is, research has found that stress leads to increased serotonin release in the amygdala of rats (Kawahara et al. 1993). Consistent with this, research has shown that sleep paralysis sufferers in Egypt who interpret their experience as a supernatural attack report greater fear during the event than Danish sufferers, who for the most part interpret sleep paralysis as merely a physiological oddity (Jalal and Hinton 2013; Jalal et al. 2014b).

Serotonin subsystems and anxiety and panic during sleep paralysis: 5-HT2CR activation

Undoubtedly, identifying the behavioral function of specific 5-HT subsystems in humans will be an important step towards illuminating the exact role of serotonin vis-à-vis sleep paralysis and fear-panic reactions. One interesting model of serotonin function, for instance, highlights the paradoxical role of 5-HT2C receptors in anxiety and panic, i.e., in response to distal versus more proximal (or imminent) threats, mediated by brain-aversion systems including the amygdala, hypothalamus, and the periaqueductal gray matter (PAG) (Deakin and Graeff 1991; see also Deakin 2013). According to this view, serotonin acts as an “anticipatory anxiety system” (or “don’t panic yet” system) where distal threats generate anxiety via the amygdala and frontal cortex, while restraining premature activation of (PAG) fight-flight reactions via serotonin (5-HT2C receptors) in the DRN. On the other hand, when “threats” are proximal (e.g., believing that death is imminent or when detecting touch, pain, or suffocation sensations [hypoxia and hypercapnia]—all of which are common during sleep paralysis [e.g., Jalal 2016; Cheyne et al. 1999b]), serotonin activates the PAG resulting in panic reactions. This account of serotonin functioning was nicely illustrated in a functional magnetic resonance imaging (fMRI) study by Mobbs et al. (2007), in which healthy volunteers played a video game where they had to control a stimulus through a visual maze, while avoiding annihilation by a threatening “ghosts” stimulus. Consistent with Deakin and Graeff’s (1991) model, the authors found that when the “ghost” was at a distance, the amygdala and frontal cortex were activated, whereas more imminent threats by the “ghost” activated PAG fight-flight mechanisms. I propose that in addition to the possible role of 5-HT2A receptors in mediating sleep paralysis fear-anxiety reactions (e.g., Frokjaer et al. 2008), these functional principals of 5-HT2CR activation might drive anxiety (via the amygdala and DRN) and panic reactions (via the PAG) during sleep paralysis. Indeed, analogous to Mobbs et al.’s (2007) video game, sleep paralysis hallucinations often include scenarios where “ghosts/demons” manifest as distal threats (e.g., lurking in the bedroom corner) and/or as proximal/imminent threats (e.g., “ghost attacks” resulting in choking and suffocation sensations, pain and spasm in limbs, etc.).

The orbitofrontal cortex and sleep paralysis visual hallucinations

It is worth noting that until recently it was thought that one’s emotional state is totally independent of the brain’s visual system. However, it is now believed that affective states such as fear are sources of top-down penetration in that they can directly influence our perceptual system (Barrett and Bar 2009; O’Callaghan et al. 2017). There are several pathways whereby this penetration could occur, including the magnocellular system and projections to the orbitofrontal cortex (Pessoa and Adolphs 2010). Neuroimaging evidence points to the orbitofrontal cortex in particular as a region that can generate top-down predictions about the emotional value of visual stimuli (Shenhav et al. 2013). The orbitofrontal cortex is a densely connected association site that receives input from various sensory modalities including limbic centers; it is strategically located to integrate cross-modal information pertinent to the interpretation of visual stimuli (Rolls 2004). The amygdala rich with 5-HT2A receptors is connected to the orbitofrontal cortex, and may provide an important source of input to the orbitofrontal cortex about the affective value of stimuli (Kawahara et al. 1993; Pessoa and Adolphs 2010; Roy et al. 2012; see also O’Callaghan et al. 2017). It is of particular interest that 5-HT2A receptors are densely concentrated in the orbitofrontal cortex (see Robbins et al. 2006). It is plausible that during sleep paralysis, the 5-HT2AR-induced amygdaloid fear circuitry mediated by the orbitofrontal cortex directly influences visual pathways and consequently hallucinations (i.e., by creating a fearful scenario that matches the individual’s emotional state). This activation of the brain’s “threat-hyper vigilance system” could facilitate top-down influence, for example, by allowing for endogenously generated somatic sensations and ambiguous cues to be interpreted as threatening and exogenously driven—i.e., as a petrifying “ghostly bedroom intruder.”

The HTR2A gene and sleep paralysis hallucinations

It is possible that individuals with increased 5-HT2A receptor density (e.g., in certain brain regions) are more prone to hallucinating during sleep paralysis. These hallucinations might be associated with the expression of the HTR2A gene on chromosome 13 that produces higher receptor density. The gene coding for HTR2A is located on the long arm of chromosome 13 (i.e., 13q) (Williams et al. 1996; see also Chen et al. 1992). Consistent with the role of serotonin in triggering hallucinations, whole-genome linkage scans have found an association between schizophrenia and markers on chromosome 13q (for a meta-analysis, see Badner and Gershon 2002). Also, alterations in the HTR2A gene and expression of it may be vulnerability factors predisposing to mood disorders, such as anxiety and depression (e.g., Islam et al. 2004). Research in particular has investigated abnormalities of 5-HT signaling vis-à-vis anxiety (e.g., Abrams et al. 2005; Keck et al. 2005; see also Unschuld et al. 2007). The fact that the 5-HT2A receptor has been implicated in psychopathology, including anxiety disorders, is of interest (Millan 2003). That is, anxiety is associated with hallucinating during sleep paralysis: One study among Egyptian college students found that having visual hallucinations during sleep paralysis was associated with trait anxiety symptomatology (Jalal and Hinton 2015). Moreover, Hinton et al. (2005) found that highly traumatized Cambodians have extremely high rates of hallucinations during sleep paralysis (i.e., 91% of episodes) compared to general populations (e.g., Jalal and Hinton 2013).


It is important to add that while sleep paralysis causes much fear and anxiety in general, the vast majority of episodes are benign and unrelated to serious pathology. Thus, there is often no need for treatment except in cases of repetitive and fearful episodes. Although clinical trials are lacking, selective serotonin reuptake inhibitors (SSRIs) are one of the most commonly used drugs in clinical practice to treat distressing sleep paralysis (Sharpless 2016; see also Sharpless and Doghramji 2015). This is unsurprising given serotonergic modulation of the sleep/wake cycle and, crucially, the anxiolytic effects of SSRIs.

In light of this hypothesis, I propose for the first time a drug to selectively target sleep paralysis hallucinations and fear reactions, namely pimavanserin. Pimavanserin is a highly selective 5-HT2A receptor inverse agonist; it has by comparison approx. 40-fold lower affinity for the 5-HT2C receptor. This makes it a promising drug candidate for targeting sleep paralysis hallucinations. As noted, pimavanserin has been found to attenuate l-DOPA-induced hallucinations (and delusions) in Parkinson’s disease. (Another candidate drug is the 5-HT2A receptor antagonist ketanserin. It is possible that ketanserin blocks the hallucinatory features of sleep paralysis, as it does hallucinogenic drugs like psilocybin [Kometer et al. 2013].) This proposed neuropharmacological account implicates gene HTR2A on chromosome 13q as the underlying cause of sleep paralysis hallucinations and could be explored using positron emission tomography.



I am indebted to Trevor W. Robbins of the University of Cambridge for his insightful suggestions and excellent feedback on the manuscript. I am also grateful to John R. Smythies of UC San Diego for stimulating discussions.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.


  1. Abrams JK, Johnson PL, Hay-Schmidt A, Mikkelsen JD, Shekhar A, Lowry CA (2005) Serotonergic systems associated with arousal and vigilance behaviors following administration of anxiogenic drugs. Neuroscience 133:983–997CrossRefGoogle Scholar
  2. Aghajanian GK, Marek GJ (1999) Serotonin and hallucinogens. Neuropsychopharmacology 21:16S–23SCrossRefGoogle Scholar
  3. Arzy S, Seeck M, Ortigue S, Spinelli L, Blanke O (2006) Induction of an illusory shadow person. Nature 443:287–287CrossRefGoogle Scholar
  4. Badner JA, Gershon ES (2002) Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 7:405–411CrossRefGoogle Scholar
  5. Barrett LF, Bar M (2009) See it with feeling: affective predictions during object perception. Philos Trans R Soc B 364:1325–1334CrossRefGoogle Scholar
  6. Bayer L, Serafin M, Eggermann E, Saint-Mleux B, Machard D, Jones BE, Mühlethaler M (2004) Exclusive postsynaptic action of hypocretin-orexin on sublayer 6b cortical neurons. J Neurosci 24:6760–6764CrossRefGoogle Scholar
  7. Botvinick M, Cohen J (1998) Rubber hands ‘feel’ touch that eyes see. Nature 391:756CrossRefGoogle Scholar
  8. Brooks PL, Peever JH (2012) Identification of the transmitter and receptor mechanisms responsible for REM sleep paralysis. J Neurosci 32:9785–9795CrossRefGoogle Scholar
  9. Brown RE, Sergeeva OA, Eriksson KS, Haas HL (2002) Convergent excitation of dorsal raphe serotonin neurons by multiple arousal systems (orexin/hypocretin, histamine and noradrenaline). J Neurosci 22:8850–8859CrossRefGoogle Scholar
  10. Buckner RL, Andrews-Hanna JR, Schacter DL (2008) The brain’s default network. Ann N Y Acad Sci 1124:1–38CrossRefGoogle Scholar
  11. Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphy K, Hobden P (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci 109:2138–2143CrossRefGoogle Scholar
  12. Chen K, Yang W, Grimsby J, Shih JC (1992) The human 5-HT2 receptor is encoded by a multiple intron—exon gene. Mol Brain Res 14:20–26CrossRefGoogle Scholar
  13. Cheyne JA (2001) The ominous numinous: sensed presence and ‘other’ hallucinations. J Conscious Stud 8:133–150Google Scholar
  14. Cheyne JA, Girard TA (2009) The body unbound: vestibular–motor hallucinations and out-of-body experiences. Cortex 45:201–215CrossRefGoogle Scholar
  15. Cheyne JA, Pennycook G (2013) Sleep paralysis postepisode distress: modeling potential effects of episode characteristics, general psychological distress, beliefs, and cognitive style. Clin Psychol Sci 1:135–148CrossRefGoogle Scholar
  16. Cheyne JA, Newby-Clark IR, Rueffer SD (1999a) Relations among hypnagogic and hypnopompic experiences associated with sleep paralysis. J Sleep Res 8:313–317CrossRefGoogle Scholar
  17. Cheyne JA, Rueffer SD, Newby-Clark IR (1999b) Hypnagogic and hypnopompic hallucinations during sleep paralysis: neurological and cultural construction of the night-mare. Conscious Cogn 8(3):319–337CrossRefGoogle Scholar
  18. Creese I, Burt DR, Snyder SH (1975) Dopamine receptor binding: differentiation of agonist and antagonist states with 3H-dopamine and 3H-haloperidol. Life Sci 17:993–1001CrossRefGoogle Scholar
  19. Deakin JF (2013) The origins of ‘5-HT and mechanisms of defence’ by Deakin and Graeff: a personal perspective. J Psychopharmacol 27:1084–1089CrossRefGoogle Scholar
  20. Deakin JF, Graeff FG (1991) 5-HT and mechanisms of defence. J Psychopharmacol 5:305–315CrossRefGoogle Scholar
  21. Eggermann E, Serafin M, Bayer L, Machard D, Saint-Mleux B, Jones BE, Mühlethaler M (2001) Orexins/hypocretins excite basal forebrain cholinergic neurones. Neuroscience 108:177–181CrossRefGoogle Scholar
  22. Eriksson KS, Sergeeva O, Brown RE, Haas HL (2001) Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci 21:9273–9279CrossRefGoogle Scholar
  23. Farrer C, Franck N, Frith CD, Decety J, Georgieff N, d'Amato T, Jeannerod M (2004) Neural correlates of action attribution in schizophrenia. Psychiatry Res Neuroimaging 131:31–44CrossRefGoogle Scholar
  24. Fisher PM, Meltzer CC, Price JC, Coleman RL, Ziolko SK, Becker C, Moses-Kolko EL, Berga SL, Hariri AR (2009) Medial prefrontal cortex 5-HT2A density is correlated with amygdala reactivity, response habituation, and functional coupling. Cereb Cortex 19:2499–2507CrossRefGoogle Scholar
  25. Frokjaer VG, Mortensen EL, Nielsen FÅ, Haugbol S, Pinborg LH, Adams KH, Svarer C, Hasselbalch SG, Holm S, Paulson OB, Knudsen GM (2008) Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol Psychiatry 63:569–576CrossRefGoogle Scholar
  26. Fukuda K, Ogilvie RD, Takeuchi T (2000) Recognition of sleep paralysis among normal adults in Canada and in Japan. Psychiatry Clin Neurosci 54:292–293CrossRefGoogle Scholar
  27. Gaebel W, Zielasek J (2009) Future classification of psychotic disorders. Eur Arch Psychiatry Clin Neurosci 259:213–218CrossRefGoogle Scholar
  28. Gerstl F, Windischberger C, Mitterhauser M, Wadsak W, Holik A, Kletter K, Moser E, Kasper S, Lanzenberger R (2008) Multimodal imaging of human early visual cortex by combining functional and molecular measurements with fMRI and PET. Neuroimage 41:204–211CrossRefGoogle Scholar
  29. González-Maeso J, Sealfon SC (2009) Psychedelics and schizophrenia. Trends Neurosci 32:225–232CrossRefGoogle Scholar
  30. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452:93–97CrossRefGoogle Scholar
  31. Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187:268–283CrossRefGoogle Scholar
  32. Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22:621–632CrossRefGoogle Scholar
  33. Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, Benham CD, Taylor SG, Routledge C, Hemmati P, Munton RP (1999) Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci 96:10911–10916CrossRefGoogle Scholar
  34. Hinton DE, Pich V, Chhean D, Pollack MH, McNally RJ (2005) Sleep paralysis among Cambodian refugees: association with PTSD diagnosis and severity. Depress Anxiety 22:47–51CrossRefGoogle Scholar
  35. Hobson JA (1995) Sleep. Scientific American library, New YorkGoogle Scholar
  36. Horvath TL, Peyron C, Diano S, Ivanov A, Aston-Jones G, Kilduff TS, van den Pol AN (1999) Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J Comp Neurol 415:145–159CrossRefGoogle Scholar
  37. Huang ZL, Qu WM, Li WD, Mochizuki T, Eguchi N, Watanabe T, Urade Y, Hayaishi O (2001) Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci 98:9965–9970CrossRefGoogle Scholar
  38. Huot P, Johnston TH, Darr T, Hazrati LN, Visanji NP, Pires D, Brotchie JM, Fox SH (2010) Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 25:1399–1408CrossRefGoogle Scholar
  39. Islam A, Thompson KS, Akhtar S, Handley SL (2004) Increased 5-HT2A receptor expression and function following central glucocorticoid receptor knockdown in vivo. Eur J Pharmacol 502:213–220CrossRefGoogle Scholar
  40. Ivanov A, Aston-Jones G (2000) Hypocretin/orexin depolarizes and decreases potassium conductance in locus coeruleus neurons. Neuroreport 11:1755–1758CrossRefGoogle Scholar
  41. Jalal B (2016) How to make the ghosts in my bedroom disappear? Focused-attention meditation combined with muscle relaxation (MR therapy)—a direct treatment intervention for sleep paralysis. Front Psychol 7:28CrossRefGoogle Scholar
  42. Jalal B (2017) Response: “Commentary: How to make the ghosts in my bedroom disappear? Focused-attention meditation combined with muscle relaxation (MR therapy)—a direct treatment intervention for sleep paralysis”. Front Psychol 8:760CrossRefGoogle Scholar
  43. Jalal B, Hinton DE (2013) Rates and characteristics of sleep paralysis in the general population of Denmark and Egypt. Cult Med Psychiatry 37:534–548CrossRefGoogle Scholar
  44. Jalal B, Hinton DE (2015) Sleep paralysis among Egyptian college students: association with anxiety symptoms (PTSD, trait anxiety, pathological worry). J Nerv Ment Dis 203:871–875CrossRefGoogle Scholar
  45. Jalal B, Ramachandran VS (2014) Sleep paralysis and “the bedroom intruder”: the role of the right superior parietal, phantom pain and body image projection. Med Hypotheses 83:755–757CrossRefGoogle Scholar
  46. Jalal B, Ramachandran VS (2017) Sleep paralysis, “the ghostly bedroom intruder” and out-of-body experiences: the role of mirror neurons. Front Hum Neurosci 11:92CrossRefGoogle Scholar
  47. Jalal B, Eskici HS, Acarturk ZC, Hinton DE (In press[a]) Beliefs about sleep paralysis in Turkey: Karabasan. Transcultural PsychiatryGoogle Scholar
  48. Jalal B, Romanelli A, Hinton DE (In press[b]) Sleep paralysis in Italy: frequency, hallucinatory experiences, and other features. Transcultural PsychiatryGoogle Scholar
  49. Jalal B, Simons-Rudolph J, Jalal B, Hinton DE (2014b) Explanations of sleep paralysis among Egyptian college students and the general population in Egypt and Denmark. Transcult Psychiatry 51:158–175CrossRefGoogle Scholar
  50. Jalal B, Romanelli A, Hinton DE (2015a) Cultural explanations of sleep paralysis in Italy: the Pandafeche attack and associated supernatural beliefs. Cult Med Psychiatry 39:651–664CrossRefGoogle Scholar
  51. Jalal B, Krishnakumar D, Ramachandran VS (2015b) “I feel contaminated in my fake hand”: obsessive-compulsive-disorder like disgust sensations arise from dummy during rubber hand illusion. PLoS One 10:e0139159CrossRefGoogle Scholar
  52. Jalal B, Kruger Q, Hinton DE (2017) Adaptation of CBT for traumatized South African indigenous groups: examples from multiplex CBT for PTSD. Cogn Behav Pract 25:335–349CrossRefGoogle Scholar
  53. Kandel ER, Schwartz JH, Jessell TM (2000) Principles of neural science, 4th edn. McGraw-Hill, New YorkGoogle Scholar
  54. Katz MM, Waskow IE, Olsson J (1968) Characterizing the psychological state produced by LSD. J Abnorm Psychol 73:1–14CrossRefGoogle Scholar
  55. Kawahara H, Yoshida M, Yokoo H, Nishi M, Tanaka M (1993) Psychological stress increases serotonin release in the rat amygdala and prefrontal cortex assessed by in vivo microdialysis. Neurosci Lett 162:81–84CrossRefGoogle Scholar
  56. Keck ME, Sartori SB, Welt T, Müller MB, Ohl F, Holsboer F, Landgraf R, Singewald N (2005) Differences in serotonergic neurotransmission between rats displaying high or low anxiety/depression-like behaviour: effects of chronic paroxetine treatment. J Neurochem 92:1170–1179CrossRefGoogle Scholar
  57. Kometer M, Schmidt A, Jäncke L, Vollenweider FX (2013) Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci 33:10544–10551CrossRefGoogle Scholar
  58. Lebedev AV, Lövdén M, Rosenthal G, Feilding A, Nutt DJ, Carhart-Harris RL (2015) Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin. Hum Brain Mapp 36:3137–3153CrossRefGoogle Scholar
  59. Liu RJ, Van Den Pol AN, Aghajanian GK (2002) Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. J Neurosci 22:9453–9464CrossRefGoogle Scholar
  60. Marek GJ, Aghajanian GK (1998a) 5-Hydroxytryptamine-induced excitatory postsynaptic currents in neocortical layer V pyramidal cells: suppression by μ-opiate receptor activation. Neuroscience 86:485–497CrossRefGoogle Scholar
  61. Marek GJ, Aghajanian GK (1998b) Serotonin2A receptorinduced EPSCs in layer V pyramidal cells of prefrontal cortex: block by group II/III metabotropic glutamate agonists. Soc Neurosci Abstr 24:1366Google Scholar
  62. McNally RJ, Clancy SA (2005) Sleep paralysis, sexual abuse and space alien abduction. Transcult Psychiatry 42:113–122CrossRefGoogle Scholar
  63. Meltzer HY, Massey BW (2011) The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 11:59–67CrossRefGoogle Scholar
  64. Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH (2010) Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology 35:881–892CrossRefGoogle Scholar
  65. Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:83–244CrossRefGoogle Scholar
  66. Mobbs D, Petrovic P, Marchant JL, Hassabis D, Weiskopf N, Seymour B, Dolan RJ, Frith CD (2007) When fear is near: threat imminence elicits prefrontal-periaqueductal gray shifts in humans. Science 317:1079–1083CrossRefGoogle Scholar
  67. Moreau AW, Amar M, Le Roux N, Morel N, Fossier P (2010) Serotoninergic fine-tuning of the excitation–inhibition balance in rat visual cortical networks. Cereb Cortex 20:456–467CrossRefGoogle Scholar
  68. Nelson K (2010) The spiritual doorway in the brain: a neurologist’s search for the God experience. Penguin, New YorkGoogle Scholar
  69. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131–181CrossRefGoogle Scholar
  70. O’Callaghan C, Kveraga K, Shine JM, Adams RB, Bar M (2017) Predictions penetrate perception: converging insights from brain, behaviour and disorder. Conscious Cogn 47:63–74CrossRefGoogle Scholar
  71. Pace-Schott EF (2008) Serotonin and dreaming. In: Monti JM, Pandi-Perumal SR, Jacobs BL, Nutt DJ (eds) Serotonin and sleep: molecular, functional and clinical aspects. Birkhauser verlag, Basel, pp 307–324CrossRefGoogle Scholar
  72. Pessoa L, Adolphs R (2010) Emotion processing and the amygdala: from a ‘low road’ to ‘many roads’ of evaluating biological significance. Nat Rev Neurosci 11:773–783CrossRefGoogle Scholar
  73. Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, Liechti ME, Seifritz E, Vollenweider FX (2017) The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol 27:451–457CrossRefGoogle Scholar
  74. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL (2001) A default mode of brain function. Proc Natl Acad Sci 98:676–682CrossRefGoogle Scholar
  75. Ramachandran VS (2012) The tell-tale brain: unlocking the mystery of human nature. Windmill books, LondonGoogle Scholar
  76. Riva G (2016) Neurobiology of anorexia nervosa: serotonin dysfunctions link self-starvation with body image disturbances through an impaired body memory. Front Hum Neurosci 10:600PubMedPubMedCentralGoogle Scholar
  77. Rizzolatti G, Fadiga L, Gallese V, Fogassi L (1996) Premotor cortex and the recognition of motor actions. Cogn Brain Res 3:131–141CrossRefGoogle Scholar
  78. Rizzolatti G, Fogassi L, Gallese V (2001) Neurophysiological mechanisms underlying the understanding and imitation of action. Nat Rev Neurosci 2:661–670CrossRefGoogle Scholar
  79. Robbins TW, Clark L, Clarke H, Roberts AC (2006) Neurochemical modulation of orbitofrontal cortex function. In: Zald DH, Rauch SL (eds) The orbitofrontal cortex. Oxford University Press, Oxford, pp 393–422CrossRefGoogle Scholar
  80. Rolland B, Jardri R, Amad A, Thomas P, Cottencin O, Bordet R (2014) Pharmacology of hallucinations: several mechanisms for one single symptom? Biomed Res Int 2014:307106CrossRefGoogle Scholar
  81. Rolls ET (2004) The functions of the orbitofrontal cortex. Brain Cogn 55:11–29CrossRefGoogle Scholar
  82. Roy M, Shohamy D, Wager TD (2012) Ventromedial prefrontal-subcortical systems and the generation of affective meaning. Trends Cogn Sci 16:147–156CrossRefGoogle Scholar
  83. Sakurai T (2007) The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 8:171–181CrossRefGoogle Scholar
  84. Saulin A, Savli M, Lanzenberger R (2012) Serotonin and molecular neuroimaging in humans using PET. Amino Acids 42:2039–2057CrossRefGoogle Scholar
  85. Schmid CL, Bohn LM (2010) Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a β-arrestin2/Src/Akt signaling complex in vivo. J Neurosci 30:13513–13524CrossRefGoogle Scholar
  86. Sharpless BA (2016) A clinician’s guide to recurrent isolated sleep paralysis. Neuropsychiatr Dis Treat 12:1761–1767CrossRefGoogle Scholar
  87. Sharpless B, Doghramji K (2015) Sleep paralysis: historical, psychological, and medical perspectives. Oxford University Press, New YorkCrossRefGoogle Scholar
  88. Shenhav A, Barrett LF, Bar M (2013) Affective value and associative processing share a cortical substrate. Cogn Affect Behav Neurosci 13:46–59CrossRefGoogle Scholar
  89. Simeon D, Knutelska M, Nelson D, Guralnik O (2003) Feeling unreal: a depersonalization disorder update of 117 cases. J Clin Psychiatry 64:990–997CrossRefGoogle Scholar
  90. Solomonova E, Nielsen T, Stenstrom P, Simard V, Frantova E, Donderi D (2008) Sensed presence as a correlate of sleep paralysis distress, social anxiety and waking state social imagery. Conscious Cogn 17:49–63CrossRefGoogle Scholar
  91. Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25:1434–1452CrossRefGoogle Scholar
  92. Tagliazucchi E, Roseman L, Kaelen M, Orban C, Muthukumaraswamy SD, Murphy K, Laufs H, Leech R, McGonigle J, Crossley N, Bullmore E (2016) Increased global functional connectivity correlates with LSD-induced ego dissolution. Curr Biol 26:1043–1050CrossRefGoogle Scholar
  93. Takeuchi T, Miyasita A, Sasaki Y, Inugami M, Fukuda K (1992) Isolated sleep paralysis elicited by sleep interruption. Sleep 15:217–225CrossRefGoogle Scholar
  94. Thakkar KN, Nichols HS, McIntosh LG, Park S (2011) Disturbances in body ownership in schizophrenia: evidence from the rubber hand illusion and case study of a spontaneous out-of-body experience. PLoS One 6:e27089CrossRefGoogle Scholar
  95. Unschuld PG, Ising M, Erhardt A, Lucae S, Kloiber S, Kohli M, Salyakina D, Welt T, Kern N, Lieb R, Uhr M (2007) Polymorphisms in the serotonin receptor gene HTR2A are associated with quantitative traits in panic disorder. Am J Med Genet B Neuropsychiatr Genet 144:424–429CrossRefGoogle Scholar
  96. Ursin R (2002) Serotonin and sleep. Sleep Med Rev 6:55–67CrossRefGoogle Scholar
  97. van der Zwaard R, Polak MA (2001) Pseudohallucinations: a pseudoconcept? A review of the validity of the concept, related to associate symptomatology. Compr Psychiatry 42:42–50CrossRefGoogle Scholar
  98. Vollenweider FX, Kometer M (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11:642–651CrossRefGoogle Scholar
  99. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9:3897–3902CrossRefGoogle Scholar
  100. Williams J, Spurlock G, McGuffin P, Mallet J, Nothen MM, Gill M, Aschauer H, Nylander PO, Macciardi F, Owen MJ (1996) Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet 347:1294–1296CrossRefGoogle Scholar

Copyright information

© The Author(s) 2018

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Department of Psychiatry and Behavioural and Clinical Neuroscience InstituteUniversity of CambridgeCambridgeUK

Personalised recommendations